lithium-chloride and Leukemia--Promyelocytic--Acute

Recently, irreversible inhibitors have attracted great interest in antitumors due to their advantages of forming covalent bonds to target proteins. Herein, some benzothiazepinone compounds (BTZs) have been designed and synthesized as novel covalent GSK-3β inhibitors with high selectivity for the kinase panel. The irreversible covalent binding mode was identified by kinetics and mass spectrometry, and the main labeled residue was confirmed to be the unique Cys14 that exists only in GSK-3β. The candidate

Topics: Animals; Apoptosis; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Female; Glycogen Synthase Kinase 3 beta; Half-Life; Humans; Isoenzymes; Kinetics; Leukemia, Promyelocytic, Acute; Male; Mice; Mice, Inbred ICR; Mice, Nude; Protein Kinase Inhibitors; Structure-Activity Relationship; Xenograft Model Antitumor Assays

We recently identified that the MEK/ERK1/2 pathway synergized with retinoic acid (RA) to restore both transcriptional activity and RA-induced differentiation in RA-resistant acute promyelocytic leukemia (APL) cells. To target the MEK/ERK pathway, we identified glycogen synthase kinase-3β (GSK-3β) inhibitors including lithium chloride (LiCl) as activators of this pathway in APL cells. Using NB4 (RA-sensitive) and UF-1 (RA-resistant) APL cell lines, we observed that LiCl as well as synthetic GSK-3β inhibitors decreased proliferation, induced apoptosis and restored, in RA-resistant cells, the expression of RA target genes and the RA-induced differentiation. Inhibition of the MEK/ERK1/2 pathway abolished these effects. These results were corroborated in primary APL patient cells and translated in vivo using an APL preclinical mouse model in which LiCl given alone was as efficient as RA in increasing survival of leukemic mice compared with untreated mice. When LiCl was combined with RA, we observed a significant survival advantage compared with mice treated by RA alone. In this work, we demonstrate that LiCl, a well-tolerated agent in humans, has antileukemic activity in APL and that it has the potential to restore RA-induced transcriptional activation and differentiation in RA-resistant APL cells in an MEK/ERK-dependent manner.

Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Leukemia, Promyelocytic, Acute; Lithium Chloride; Mice; Mitogen-Activated Protein Kinase Kinases; Oncogene Proteins, Fusion; Tretinoin

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML). With the application of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), APL becomes one of best prognosis of leukemia. However, ATRA and ATO are not effective against all APLs. Therefore, a new strategy for APL treatment is necessary. Here, we investigated whether lithium chloride (LiCl), a drug used for the treatment of mental illness, could promote apoptosis in human leukemia NB4 cells. We observed that treatment with LiCl significantly accelerated apoptosis in NB4 cells and led to cell cycle arrest at G2/M phase. Moreover, LiCl significantly increased the level of Ser9-phosphorylated glycogen synthase kinase 3β(p-GSK-3β), and decreased the level of Akt1 protein in a dose-dependent manner. In addition, LiCl inhibition of c-Myc also enhanced cell death with a concomitant increase in β-catnin. Taken together, these findings demonstrated that LiCl promoted apoptosis in NB4 cells through the Akt signaling pathway and that G2/M phase arrest was induced by increase of p-GSK-3β(S9).

Topics: Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Leukemia, Promyelocytic, Acute; Lithium Chloride

Topics: Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Lithium Chloride; Tumor Cells, Cultured

Traditional RNA isolation methods use chaotropic agents and anionic detergents to lyse cells and solubilize nucleic acids. In contrast, the cationic surfactant, Catrimox-14, lyses cells and simultaneously precipitates RNA, thereby protecting it from RNases. We describe and compare four methods for extracting RNA from cultured cells that differ in the technique used to extract the RNA from the precipitate. The first uses a high-salt solution (guanidinium isothiocyanate). In the second, the RNA is extracted with a polar solvent (formamide). The third involves conversion of the RNA to the sodium salt by treatment of the precipitate in situ with sodium acetate in ethanol. The fourth uses 2 M lithium chloride to convert the RNA in the pellet to the lithium salt in situ. We applied these methods to human leukemia cells growing in culture and each method resulted in excellent yields of RNA (typically 23 micrograms/million K562 cells, 13 micrograms/million HL-60 cells) over a wide range of cell concentrations (1 x 10(5) - 3 x 10(7)/ml) and of good to excellent quality as judged by agarose electrophoresis and UV absorbance data (OD260/280 1.90-2.05). The advantages and limitations of each method are discussed.

Topics: Acetates; Acetic Acid; Cations; Detergents; Electrophoresis, Agar Gel; Formamides; Guanidines; Humans; Isothiocyanates; Leukemia, Erythroblastic, Acute; Leukemia, Promyelocytic, Acute; Lithium Chloride; Quaternary Ammonium Compounds; RNA, Neoplasm; Trimethyl Ammonium Compounds; Tumor Cells, Cultured

The use of lithium chloride in manic-depressive patients and in patients receiving myelo-suppressive cancer chemotherapeutic agents is accompanied by a sustained leukocytosis due to an increase in granulocyte production. This property suggests that lithium chloride may have effects on hematopoietic differentiation. Treatment of cultured WEHI-3B D+ murine myelomonocytic and HL-60 human promyelocytic leukemia cells with millimolar concentrations of lithium chloride resulted in concentration-dependent increases in the number of differentiated myeloid cells, as determined by the ability of the cells to reduce nitroblue tetrazolium and by the binding of myeloid specific antibodies, and was associated with an inhibition of cellular proliferation. The effects of lithium chloride on growth and differentiation were antagonized by KCl, whereas NaCl had little effect. The induction of leukemic cell maturation by lithium chloride was markedly enhanced by the addition of low levels of retinoic acid. In contrast, other differentiation inducing agents (i.e. dimethyl sulfoxide and selenazofurin) had no effect on the degree of maturation induced by lithium. These findings suggest that the combination of lithium chloride and retinoic acid may have clinical utility in the treatment of leukemia through the induction of terminal differentiation.

Topics: Animals; Cell Differentiation; Chlorides; Growth Substances; Hematopoiesis; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Lithium; Lithium Chloride; Mice; Tretinoin; Tumor Cells, Cultured

HL-60 cells were grown in culture and their proliferative behaviour and response to lithium were studied. Treatment of cells with lithium concentrations of up to 5 mM enhanced cell proliferation, however above 5 mM lithium, cell growth was inhibited. Cell viability remained above 90% with concentrations of lithium below 10 mM. With increasing concentrations of lithium cell death increased rapidly to about 70% after 3 days at 50 mM. DNA synthesis was also strongly inhibited by concentrations of lithium above 5 mM. At 50 mM lithium, [3H]-thymidine incorporation was 1%. Electron microscopy seems to indicate that the plasma membrane is the main target for lithium cytotoxicity, whilst lithium uptake studies suggest that cytotoxicity might be related to the accumulation of lithium within the cells.

Topics: Cell Division; Chlorides; DNA Replication; Humans; Leukemia, Promyelocytic, Acute; Lithium; Lithium Chloride; Microscopy, Electron, Scanning; Tumor Cells, Cultured